 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | FH-TCR-T?s?? / Fred Hutchinson Cancer Center
Trial completion date, Trial primary completion date, Metastases: Mesothelin-Specific T-Cells (FH-TCR-T?s??) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Jan 8, 2024
P1, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Center
Trial completion date: Sep 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Jun 2024
- | FH-TCR-T?s?? / Fred Hutchinson Cancer Center
Trial completion date, Trial primary completion date, Metastases: Mesothelin-Specific T-Cells (FH-TCR-T?s??) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Sep 15, 2023
P1, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Center
Trial completion date: Sep 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Jun 2024 Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Dec 2023
- || FH-TCR-T?s?? / Fred Hutchinson Cancer Center
Enrollment open, Metastases: Mesothelin-Specific T-Cells (FH-TCR-T?s??) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Feb 2, 2023
P1, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Center
Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Dec 2023 Suspended --> Recruiting
- ||| FH-TCR-T?s?? / Fred Hutchinson Cancer Center
Trial suspension, Metastases: Mesothelin-Specific T-Cells (FH-TCR-T?s??) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Jan 9, 2023
P1, N=15, Suspended, Sponsor: Fred Hutchinson Cancer Center
Suspended --> Recruiting Recruiting --> Suspended
- | FH-TCR-T?s?? / Fred Hutchinson Cancer Center
Trial completion date, Trial primary completion date, Metastases: Mesothelin-Specific T-Cells (FH-TCR-T?s??) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Apr 20, 2022
P1, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Center
Recruiting --> Suspended Trial completion date: Nov 2037 --> Apr 2024 | Trial primary completion date: Nov 2022 --> Jun 2023
- || FH-TCR-T?s?? / Fred Hutchinson Cancer Center
Enrollment open, Metastases: Mesothelin-Specific T-Cells (FH-TCR-T?s??) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Aug 25, 2021
P1, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial completion date: Nov 2037 --> Apr 2024 | Trial primary completion date: Nov 2022 --> Jun 2023 Not yet recruiting --> Recruiting
- || FH-TCR-T?s?? / Fred Hutchinson Cancer Center
Trial initiation date, Metastases: Mesothelin-Specific T-Cells (FH-TCR-T?s??) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Apr 29, 2021
P1, N=15, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Initiation date: May 2021 --> Aug 2021
- | FH-TCR-T?s?? / Fred Hutchinson Cancer Center
New P1 trial, Metastases: Mesothelin-Specific T-Cells (FH-TCR-T?s??) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Mar 21, 2021
P1, N=15, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center